T he somatosensory system helps us evaluate our environment, for instance, alerting us to harmful or potentially damaging conditions. Through this system, noxious stimuli generate itch and pain percepts. The sensation of itch, which warns us to the presence of organisms or substances on or in the skin, triggers removal of these agents. In contrast, painful stimuli produce immediate escape to prevent tissue damage. The presence of painful and itch-inducing stimuli is detected by sensory neurons with cell bodies in the dorsal root ganglion (DRG) or trigeminal ganglion. These nociceptive and pruriceptive neurons transmit signals to the dorsal horn of the spinal cord or spinal trigeminal nucleus.
Results
Somatostatin and Nppb are co-expressed in a subset of DRG neurons. Neuropeptides are known to serve various somatosensory signaling roles 27 . We recently studied the neuropeptides neuromedin B (NMB) and Nppb and demonstrated that they are involved in pain and itch mechanisms, respectively 3, 28 . In addition to NMB and Nppb, there are many other neuropeptides expressed in DRG. To characterize these in greater detail, we compared the expression profiles of several neuropeptides ( Fig. 1a and Supplementary Fig. 1) . Notably, the expression pattern of somatostatin is very similar to that of Nppb (Fig. 1a ), and single cell transcriptomic analyses suggest that they are co-expressed 17, 18, 29 .
To determine the extent of overlap in expression of these neuropeptides, we performed double-label in situ hybridization (ISH). Figure 1b shows that there was virtually complete co-expression (99% overlap: 161 of 163 Sst + or Nppb + neurons). This raised questions of how these neuropeptides are used by the same neuron and what the function is of these neurons.
Optogenetic activation of somatostatin + primary afferent neurons elicits itch behavior. Previously, we demonstrated that Nppb is both necessary and sufficient to produce itch behavior 3 , suggesting that Nppb + somatostatin + neurons function as pruriceptors. The tight correspondence in gene expression of somatostatin and Nppb allowed us to test this by genetically manipulating these neurons in mice in which Cre is knocked into the somatostatin locus (Sst Cre ), as was performed recently 19 . We first investigated whether Cre mediates appropriate reporter expression in Sst Cre mice. Double-label ISH analysis of tissue from reporter-crossed mice (Sst Cre ;Ai9) demonstrated that the majority of reporter-labeled neurons co-expressed Nppb ( Supplementary Fig. 2a ; 107 of 139 tdT-labeled neurons are Nppb + ), and fibers from these neurons innervate the skin ( Supplementary  Fig. 2b ). This indicates that Sst Cre marks the majority of somatostatin + primary afferents. The rodent cheek-itch model is widely used to distinguish itch and pain behaviors, and we adapted this by replacing pruritogen injection with optogenetic stimulation. We expressed channelrhodopsin (ChR2) in somatostatin neurons (Sst Cre ;Ai32 mice). To ensure that ChR2 was not expressed in MrgA3 pruriceptors 2 , we analyzed co-expression of ChR2 with both Nppb and MrgA3 (Fig. 2a ). We found that the majority of Cre-mediated expression (of ChR2) was restricted to Nppb + neurons (130 of 176 neurons). In addition, almost no MrgA3 + neurons co-expressed ChR2 (1 of 176) . This confirmed that the Nppb + and MrgA3 + neurons were separate populations 17, 18, 29 . To establish that somatostatin neurons can be optogenetically activated and to determine the frequency they can follow, we initially measured responses to light in isolated sensory neurons ( Supplementary Fig. 2c ). Somatostatin neurons could follow optogenetic activation up to 20 Hz, and we used this frequency for behavioral assays. We activated ChR2 + somatostatin + neurons through a light cannula surgically implanted within 1 mm of the dorsal surface of the trigeminal ganglion ( Fig. 2b) . Notably, optogenetic activation produced robust scratching responses localized to the ipsilateral cheek ( Fig. 2c ). Responses to optogenetic stimulation were similar to those induced by injection of histamine into the cheek, except that optogenetic stimulation only elicited scratching, while histamine also evoked cheek wipes. We observed almost no scratching of the contralateral cheek and no behavioral responses to illumination with a nonactivating wavelength of light. These results demonstrated that activating somatostatin afferents was sufficient to generate selective itch behavior.
Somatostatin interacts with both Nppb and GRP in itch signaling.
Our optogenetic experiments showed that itch can be induced by activation of somatostatin + primary afferents, suggesting that somatostatin released from these cells acts as an itch transmitter. However, it is unclear how somatostatin interacts with the itch transmitters Nppb and GRP 3, 4 . A simple model would posit that the three neuropeptides interact in such a way as to have additive effects on itch. To investigate this, we measured scratching elicited by Nppb and GRP alone, and compared those responses with scratching elicited by Nppb and GRP co-administered with the somatostatin-receptor agonist octreotide. Furthermore, we compared Nppb-and GRP-induced scratching with that evoked by co-administration of Nppb or GRP together with the specific somatostatin Sst2-receptor antagonist CYN 154806. We predicted that if somatostatin is involved in GRPand Nppb-induced itch, then octreotide would increase scratching induced by these neuropeptides, while CYN 154806 would have the opposite effect. Indeed, we found that octreotide potentiated Nppband GRP-induced itch behavior, whereas CYN 154806 attenuated these responses ( Fig. 3a,b ). CYN 154806 also attenuated histamineinduced itch behavior, as would be expected if somatostatin has a physiological role in itch (Fig. 3c ). This indicates that somatostatin, GRP and Nppb are transmitters in a connected itch circuit.
Spinal inhibition of itch involves the dynorphin subset of B5-I neurons. Previously, somatostatin was shown to hyperpolarize B5-I interneurons, and the itching caused by intrathecal octreotide was absent in mice lacking these neurons 15 . This led to the suggestion that somatostatin-induced itch was mediated by disinhibition involving these cells. However, it was subsequently reported that B5-I neurons are not involved in itch behavior 9 . Furthermore, B5-I neurons can be subdivided into two populations, which show only limited (~20%) overlap, based on expression of dynorphin and nNOS 13, 15 , and it was not clear which of these was involved in modulating itch. We therefore investigated which type of B5-I neuron is required for pruritogen-and somatostatin-induced itch by manipulating the activity of either dynorphin + or nNOS + neurons. We engineered mice in which we could individually interrogate these populations, based on expression of designer receptors exclusively activated by designer drugs (DREADDs) 30 (Fig. 4a ). Specifically, we injected adeno-associated virus (AAV) coding for the Credependent Gq-coupled DREADD hM3Dq (DREADDq) fused to mCherry into one side of the lumbar dorsal horn 31 of Pdyn Cre and nNOS CreERT2 mice (Fig. 4b) . Notably, we found that AAV infection resulted in expression of mCherry in the appropriately targeted populations and that chemogenetic activation of neurons with clozapine-N-oxide (CNO) caused c-Fos expression in the majority (92-95%) of mCherry + cells, confirming that both populations were activated ( Fig. 4b-d and Supplementary Fig. 3 ). In both genotypes, mCherry + cells were most numerous in laminae I-II and scattered through deeper laminae, consistent with the distribution of cells that express nNOS and preprodynorphin (PPD). nNOS + cells can be readily detected with immunocytochemistry, and we confirmed that in nNOS CreERT2 mice, 429 of 431 (99.5%) of mCherry + cells in laminae I-II were nNOS-immunoreactive. Since both nNOS and dynorphin are also expressed in some excitatory interneurons, we confirmed expression of mCherry and c-Fos in inhibitory interneurons by immunostaining for the transcription factor Pax2 and/or the Sst 2a receptor, both of which are restricted to inhibitory interneurons in this region 15, 31, 32 . Close to the injection sites in the nNOS CreERT2 mice, mCherry was present in 71.8% (range: 58.8-91.7%) of Sst 2a + (inhibitory) nNOS cells. In the Pdyn Cre mice, 44% (range: 33.8-50.8%) of cells that contained both Pax2 and Sst 2a were mCherry + , and since PPD is present in 54% of Sst 2a + neurons in laminae I-II 13 , we estimate that 82% of inhibitory dynorphin cells expressed DREADDq in this region. We also confirmed that the DREADDq was not expressed in primary afferents by examining ipsilateral L4 DRGs (4 mice of each genotype) and observing that there were no mCherry-immunoreactive neurons in any of these ganglia ( Supplementary Fig. 4 ).
If somatostatin induces itch by a disinhibitory mechanism involving B5-I neurons, we would expect that chemogenetic activation of one or both of these populations would attenuate pruritogen-evoked itch behavior by increasing inhibitory tone. Consistent with this prediction, we found that activation of dynorphin neurons with CNO markedly attenuated itch responses to the itch-inducing agent chloroquine injected intradermally into the ipsilateral calf ( Fig. 4e and Supplementary Fig. 4 ). In contrast, activation of nNOS neurons had no effect on pruritogen-induced itch (Fig. 4e ). Furthermore, in a separate series of experiments involving Pdyn Cre mice, we tested the effect of intrathecal administration of AAV coding for DREADDq on itch behavior in response to pruritogens injected into the nape of the neck. Administration of CNO to activate the dynorphin neurons attenuated both histamine-and chloroquine-evoked itch. Notably, scratching evoked by intrathecal administration of octreotide was also attenuated when the dynorphin neurons were activated by CNO ( Fig. 4f) , consistent with the suggestion that somatostatin induces itch by a disinhibitory mechanism involving the dynorphin neurons.
Since activation of nNOS neurons did not alter itch behavior, we investigated their function by testing other somatosensory modalities. Additionally, we wondered whether, in addition to their antipruritic role, dynorphin neurons could modulate responses to other stimuli. We therefore examined behavioral responses to noxious thermal and mechanical stimulation following chemogenetic activation of dynorphin and nNOS neurons in lumbar dorsal horn. Notably, activation of nNOS neurons decreased sensitivity to both noxious heat and mechanical stimuli ( Fig. 5a,b ), suggesting that they have an antinociceptive, but not an antipruritic, role. Unexpectedly, we found that, as well as inhibiting itch, chemogenetic activation of dynorphin neurons markedly increased sensitivity to von Frey hairs, although it had no effect on responses to heat stimulation ( Fig. 5a,b ). This pronociceptive effect is likely mediated through activation of dynorphin + excitatory interneurons, as these consistently showed c-Fos expression after treatment with CNO, and included vertical cells ( Supplementary Figs. 3a and 5a ), which are thought to innervate nociceptive projection neurons in lamina I 33 . We also noticed that mCherry + excitatory cells were particularly numerous in the medial third of the dorsal horn, where they accounted for ~50% of the mCherry population, whereas they only constituted 12% of mCherry cells elsewhere in the superficial laminae. We recently reported that PPD + excitatory neurons are concentrated in the medial part of laminae I-II in the L4 segment, suggesting an association with regions innervated by glabrous skin 13 . To confirm this, we immunostained sections through lumbar and cervical enlargements of wild-type mice and compared the distribution of inhibitory (Pax2 + ) and excitatory (Pax2 -) PPDimmunoreactive neurons. In both enlargements, the excitatory cells were largely restricted to glabrous skin territory, identified by lack of input from VGLUT3 + C-low threshold mechanoreceptors, which are restricted to hairy skin 34 (Fig. 5c-g and Supplementary  Fig. 5b ,c). It is therefore likely that excitatory dynorphin neurons are largely restricted to regions of dorsal horn innervated by glabrous skin and that they accounted for the mechanical hyperalgesia that we observed when von Frey hairs were applied to the plantar surface of the foot. The calf-itch model activates cells in the middle third of the superficial dorsal horn within the L3 segment 35 . Excitatory PPD cells were rarely present in this region ( Fig. 5c -g) and are therefore unlikely to be involved in the antipruritic effect seen in the CNOtreated mice. Together, these results establish that dynorphin-and nNOS-containing interneurons modulate responses to several sensory modalities and produce distinct behavioral effects.
Somatostatin and dynorphin interact with Nppb signaling at the level of GRPR neurons. Previously it was reported that dynorphin can attenuate itch through the KOR and that KOR antagonists can induce itch 15 . However, it is unclear how dynorphin acting on KORs modulates the itch evoked by somatostatin and Nppb. To examine this, we again took a pharmacological approach to determine the sequence in the itch pathway involving these neurotransmitters. First, our results placed dynorphin downstream of somatostatin ( Fig. 4f ), and therefore we reasoned that the KOR agonist ICI199441 should block scratching responses induced by octreotide 15 . Second, it follows that if the somatostatin receptor is upstream of the action of KOR, we would predict that administration of a somatostatinreceptor antagonist would not affect itch induced by the KOR antagonist norbinaltorphimine. Lastly, since peripherally induced itch is inhibited by the KOR agonist, then scratching evoked by histamine and Nppb should also be attenuated by the KOR agonist 15 .
As expected, we found that the KOR agonist attenuated somatostatin-induced itch, that KOR antagonist-induced itch was unaffected by somatostatin receptor antagonist and that both histamine-and Nppb-induced itch were also attenuated by the KOR agonist ( Fig.  6a,b ). Together, these results further substantiate the pathway for somatostatin-induced itch, through disinhibition involving the dynorphin subset of B5-I neurons, and provide additional evidence that this pathway interacts with Nppb signaling.
Our results indicate that somatostatin-induced itch is mediated through disinhibition involving dynorphin + interneurons and that somatostatin can potentiate Nppb signaling. However, the site of interaction between these pathways is unknown. This could be at the level of either Npr1 neurons or GRPR neurons. To investigate this, we used conjugated toxins to generate selective lesions in the Nppb and GRP pathways 3, 5 , and we pharmacologically blocked GRPR. Specifically, we used Nppb-saporin and GRP-saporin to ablate Npr1-and GRPR-expressing dorsal horn neurons, respectively, and we inhibited GRPR with GRPR antagonists. By exploiting octreotide-triggered and KOR-antagonist-triggered itch behavior, we could then examine the requirement of Nppb and GRP neurons for these types of itch. We reasoned that a block at the site of intersection would attenuate itch responses, while a block upstream of this site would not. As expected, we found that one population of neurons was required: ablation of GRPR neurons, and treatment with GRPR antagonist, profoundly reduced the itch elicited by both octreotide and the KOR antagonist, as well as that evoked by histamine ( Fig. 6c-e ). In contrast, elimination of Npr1 neurons attenuated histamine-induced itch, but had no effect on octreotide-evoked and KOR-antagonist-evoked itch, suggesting that somatostatin and dynorphin act downstream of Npr1 cells ( Fig. 6f-h ). Together, these data suggest a model for somatostatin-mediated itch that involves the dynorphin + subset of B5-I neurons, which suppress transmission at the level of the GRPR cells ( Fig. 6i ).
Somatostatin is required for normal itch and pain responses.
Our findings suggest that the itch-inducing effect of somatostatin is mediated at least in part by dynorphin neurons. However, the origin of the somatostatin that acts on these neurons to cause itch is unknown. Somatostatin is expressed by both primary afferents and excitatory spinal cord interneurons 25, 36 . Either or both of these populations might be the source of the somatostatin that is involved in regulating itch. To address this issue and provide further evidence (c) histamine (100 µ g) or a combination of histamine and CYN154806 (1 µ g) revealed that Nppb-and GRP-evoked itch behavior is significantly potentiated by octreotide and attenuated by CYN154806 (a,b). In addition, CYN154806 significantly attenuated histamine-induced scratching. Significant differences between indicated treatment groups for a and b were assessed using one-way ANOVA with post hoc Sidak's tests: octreotide-induced scratching was significantly changed by the addition of Nppb (*P = 0.0002) and Nppb-elicited scratching was significantly reduced by CYN (*P = 0.0053), F 3,19 = 0.6796. Octreotide (oct)-induced scratching was significantly changed by the addition of GRP (*P = 0.0001) and GRP-elicited scratching was significantly reduced by CYN (*P = 0.0036) F 3,20 = 0.5998. Data represent means ± s.e.m. (in a, n = 6 Oct, 5 Nppb + oct, 6 Nppb, 6 Nppb + CYN; in b, 6 Oct, 6 GRP + oct, 6 GRP, and 6 GRP + CYN mice). Significant differences for c were assessed using two-sided unpaired Student's t test (*P = 0.002). Data represent means ± s.e.m. (n = 9 histamine and 8 histamine + CYN mice).
that somatostatin acts as a mediator of itch in vivo, we generated mice in which somatostatin could be eliminated in specific cell types (Fig. 7a ). The resulting Sst loxP/loxP (hereafter Sst f/f ) mice were crossed with Trpv1 cre , Lbx1 cre and Wnt1 cre lines to eliminate somatostatin from DRG neurons, dorsal horn neurons and both classes of neurons, respectively. The resulting mice were born at expected Mendelian ratios, appeared healthy and showed none of the phenotypic abnormalities present in global somatostatin-knockout mice 37 . ISH confirmed selective loss of somatostatin mRNA in the expected tissues ( Fig. 7b ). Our results from blocking the somatostatin receptor ( Fig. 3 ) led to the prediction that mice lacking somatostatin in the dorsal horn should display reduced responses to itch-inducing agents. To test this, we assessed behavioral responses of the mutant mice to several pruritogens. As Supplementary Fig. 3 for numbers). Arrowhead points to a Pax2 + (inhibitory) Sst 2aexpressing neuron that lacks mCherry; this cell was not c-Fos + . Scale, 10 μ m. d, Chemogenetic activation in the nNOS CreERT2 mouse. Transverse section of spinal cord taken from a nNOS CreERT2 mouse injected with AAV2-flex-hM3Dq-mCherry and treated with CNO 2 h before perfusion fixation. The section was immunostained to reveal mCherry (red), Sst 2a (blue), nNOS (gray) and c-Fos (green). Five cells showing varying levels of nNOS-immunoreactivity are visible. Two of these (asterisks) are stained for mCherry and Sst 2a (inhibitory nNOS cells) and are c-Fos + . Of the three cells with weak nNOSimmunoreactivity, one (arrow) is positive for mCherry and c-Fos, but lacks Sst 2a , and is therefore likely an excitatory interneuron. The other two are not labeled with either mCherry or c-Fos: one of these is an Sst 2a -positive inhibitory neuron (single arrowhead), while the other lacks Sst 2a and is therefore likely to be an excitatory neuron (double arrowhead). This shows chemogenetic activation of nNOS cells, including inhibitory (Sst 2a -expressing) interneurons. Similar results were obtained in experiments on 3 CNO-treated animals (see Supplementary Fig. 3 for numbers). Scale, 20 μ m. e, The time spent biting the calf in response to intradermal injection of chloroquine (100 μ g) was reduced following chemogenetic activation (CNO) in Pdyn Cre mice, but there was no effect on itch responses in nNOS CreERT2 animals. Significant differences were assessed using two-sided unpaired Student t tests (t 21 = 2.92, *P = 0.0082 for Pdyn Cre mice and t 23 = 0.875, P = 0.391 for NOS CreERT2 mice; ns, not significant). Data represent means ± s.e.m. (n = 11, 12, 12, and 13 animals, for Pdyn Cre mice + CNO, Pdyn Cre mice + vehicle, nNOS CreERT2 mice + CNO and nNOS CreERT2 mice + vehicle, respectively). mCherry-labeled injection sites (as shown in b) were verified in all of these experiments. Veh, vehicle. f, DREADDq activation following intrathecal injection of AAV2-flex-hM3Dq significantly reduced numbers of itch bouts in Pdyn Cre mice injected into the nape of the neck with histamine (100 µ g) and chloroquine (100 µ g), and also when octreotide (100 ng) was administered intrathecally. Significant differences were assessed using two-sided unpaired Student's t tests (t 10 = 3.017, 3.053 and 4.861; *P = 0.013, 0.0122 and 0.0007 for mice injected with histamine, chloroquine and octreotide, respectively). Data represent means ± s.e.m. (n = 6 animals per group).
anticipated, we found that mice lacking somatostatin in both peripheral and spinal cord neurons (Sst f/f ;Wnt1 cre ), exhibited significant itch deficits to all pruritogens tested ( Fig. 7c ). In contrast, mice lacking somatostatin in either primary afferents (Sst f/f ;Trpv1 cre ) or dorsal horn interneurons (Sst f/f ;Lbx1 cre ) displayed itch behaviors similar to those of control littermates ( Supplementary Fig.  6a ,b). These results provide further evidence that somatostatin is required for itch transmission in vivo and showed that somatosta-tin from both primary afferents and spinal cord interneurons contributed to normal itch behavior. The finding that somatostatin released from interneurons was required for normal itch transmission led us to search for further evidence supporting such a role. We investigated Pdyn Cre mice that had received spinal injections of AAV coding for Cre-dependent enhanced green fluorescent protein (eGFP), to allow visualization of dynorphin neurons. We identified eGFP + cells with Med.
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Med. tonic or transient firing patterns (characteristic of inhibitory neurons 38 ) and found that all of these cells (8 of 8) were hyperpolarized by bath-applied somatostatin ( Supplementary Fig. 7) , consistent with expression of Sst 2a receptor by 91% of inhibitory dynorphin cells 13 . In anatomical studies, axonal boutons belonging to somatostatin + interneurons can be recognized by their co-expression of somatostatin and VGLUT2, whereas somatostatin primary afferent terminals have very low or undetectable levels of VGLUT2-immunoreactivity 36 . We found, as expected, that most eGFP + cell bodies in superficial dorsal horn (78%) were Sst 2a -immunoreactive and that these lay within a dense plexus of boutons that contained both somatostatin and VGLUT2, and therefore presumably originated from local somatostatin interneurons.
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In addition, all of the cells examined had numerous contacts from somatostatin + VGLUT2 + boutons on their cell bodies and dendrites ( Supplementary Fig. 8 ). These findings suggest that somatostatin released from axons of local interneurons acts on dynorphin + inhibitory interneurons to cause disinhibition. In addition to a role in itch, somatostatin has been proposed to be either pronociceptive [22] [23] [24] or analgesic 39, 40 . To investigate this, we a, Itch responses to intradermally injected histamine (100 µ g), and to intrathecally administered Nppb (5 µ g) and octreotide (100 ng) were significantly attenuated when the KOR agonist ICI199441 (100 ng) was co-administered. Significant differences were assessed for indicated treatment groups using two-sided unpaired Student's t tests (t 9 = 7.059, t 10 = 10.14, t 9 = 11.78; *P = 0.0001 for all comparisons). Data represent means ± s.e.m. (n = 6 histamine, 5 histamin + KOR agonist, 6 Nppb, 6 Nppb + KOR agonist, 5 octreotide and 6 octreotide + KOR agonist animals). b, CYN154806 (1 µ g) does not affect itch behavior induced by norbinaltorphimine (100 µ g); differences were assessed using two-sided unpaired Student's t tests (t 12 = 2.708, P = 0.06; ns, nonsignificant). Data represent means ± s.e.m. (n = 7 KOR antagonist, 7 KOR antagonist + CYN animals). c-e, Scratching bouts induced by (c) histamine (100 µ g), (d) octreotide (100 ng) and (e) norbinaltorphimine (100 µ g) were reduced in mice treated with GRP-saporin and in those treated with GRPR antagonist; significant differences were assessed for indicated treatment groups using one-way ANOVA with post hoc Sidak's tests (F 2,15 = 42.48, F 2,15 = 37.87, F 2,16 = 29; *P = 0.0001 for all comparisons). Data represent means ± s.e.m. (n = 6 histamine untreated, 6 histamine GRP-saporin, 6 histamine GPR antagonist, 6 octreotide untreated, 6 octreotide GRP-saporin, 6 octreotide GRP antagonist, 6 KOR antagonist untreated, 7 KOR antagonist GRPsaporin and 6 KOR antagonist GRP-antogonist animals), f-h, Nppb-saporin treatment reduced scratching bouts to histamine, but not to octreotide or norbinaltorphimine; differences between treatment groups were assessed using two-sided unpaired Student's t tests (t 5 = 4.953, *P = 0.004 histamine; tested the nociceptive behavior of conditional Sst f/f mice. Notably, we found that mice lacking somatostatin in DRG neurons (Sst f/f ;Trpv1 cre ) displayed dramatically increased sensitivity to noxious heat (Fig. 8) .
In contrast, Sst f/f ;Lbx1 cre animals exhibited normal responses to noxious heat, while Sst f/f ;Wnt1 cre mice displayed responses similar to those of Sst f/f ;Trpv1 cre mice. These results indicate that somatostatin released from primary sensory neurons normally suppresses nociceptive responses. This might result from effects in the spinal cord or be due to tonic release of somatostatin from Nppb afferents acting on peripheral endings of nociceptive afferents, as reported previously 20, 21, 41 . Conditional Sst f/f mice also exhibit phenotypic differences in withdrawal thresholds to von Frey hairs ( Supplementary  Fig. 6c ), suggesting a contribution of somatostatin to this behavior.
Notwithstanding the mechanism involved, the phenotype of somatostatin-deficient mice demonstrates that somatostatin released from primary afferents contributes to the inhibition of pain.
Discussion
Here using optogenetics, chemogenetics, pharmacology and conditional genetic knockouts, we delineated roles for somatostatin in itch and pain sensation. First, using optogenetic activation, we showed that sensory neurons expressing somatostatin are sufficient to evoke itch behavior (Fig. 2) . Second, we demonstrated that somatostatin directly potentiated itch elicited by Nppb and GRP and that a somatostatin-receptor antagonist attenuated histaminergic itch ( Fig. 3 ). Third, genetic knockout of somatostatin established that it is required for normal itch behavior (Fig. 7) , and our studies defined a disinhibitory spinal cord microcircuit through which somatostatin modulates itch (Figs. 3, 4 and 6 ). Lastly, we showed that somatostatin released from primary afferents was involved in inhibiting pain behavior (Fig. 8) . Therefore, our studies revealed, at both molecular and cellular levels, the mechanisms by which somatostatin modulates itch, and we showed that somatostatin also played an important role in heat nociception.
The co-localization of somatostatin and Nppb in a subclass of sensory neurons raised the question of how these neuropeptides interact in itch processing. Our results revealed that they act on distinct neural substrates and that the pathways engaged by these transmitters, although initially separate, converged and interacted (Figs. 3, 4 and 6) . Although somatostatin presumably acts at least partly through dynorphin or KOR signaling to regulate itch, inhibition involving GABA and glycine has also been shown to play a critical role in suppressing pruritogen-evoked activity 31, 42, 43 . GABA, the principal fast transmitter used by the dynorphin and galanin interneurons 44 , is therefore also likely to have contributed to the antipruritic effect of stimulating the dynorphin neurons and to be involved in somatostatin-evoked itch. Since neuropeptides have longer-lasting actions than amino-acid transmitters, we suggest that peptidergic mechanisms involving somatostatin and dynorphin probably modify the excitability of neurons in the spinal cord to control longer-term behavioral responses, whereas fast transmitters underlie the rapid suppression of itch by counterstimuli. Recently, another study examined the effects of chemogenetic and optogenetic activation of spinal cord somatostatin neurons and found that this potentiates mechanical sensitivity 26 , in line with the proposed role of these neurons in gating mechanical pain 9 . In addition, the authors reported that low-frequency optogenetic stimulation of these neurons increases histamine-evoked scratching behavior and that this effect is reduced by intrathecal administration of the somatostatin receptor antagonist CYN 154806 (250 ng) 26 , suggesting that it is mediated at least in part by somatostatin released from these cells. However, this finding is difficult to interpret, because we show here that intrathecal treatment with a somewhat higher dose (1 μ g) of CYN 154806 strongly suppressed histamine-evoked itch (Fig. 3c ). Nonetheless, these findings are consistent with our conclusion that somatostatin release from the spinal cord contributes to itch neurotransmission. Previously we showed that somatostatin is expressed in the majority of GRP neurons 45 , and so co-release of GRP and somatostatin from these cells could independently contribute to itch.
Molecularly defined classes of primary afferent neurons that detect and transmit signals for thermal, tactile and itch stimuli have been identified, and it has been suggested that sensation is primarily encoded by these specifically tuned receptor cells 1 . However, since somatostatin afferents express TRPV1, they could be activated by noxious stimuli. Nonetheless, our optogenetic findings show that selective stimulation of these cells results in itch, but not pain behaviors. This suggests that a coding mechanism allows these two types of stimulus to be distinguished. One potential mechanism would be the 'leaky gate' model 46 . This proposes that although pruritic and nociceptive inputs converge on GRP neurons, frequency coding by these cells determines whether pain or itch behavior is evoked, through a feedforward inhibition involving enkephalinergic neurons. As predicted by this model, Sun et al. 46 found that ablation of GRP cells resulted in a dramatic reduction of itch and an increase in certain types of pain. However, their ablation appears to have extended beyond the GRP neurons, since they reported a marked loss of cells that express PKCγ , which shows minimal overlap with GRP 45, 47 . Loss of additional populations of excitatory interneurons therefore complicates interpretation of their behavioral findings. Consistent with the idea that somatostatin + Nppb + neurons are dedicated itch chemoreceptors, the IL31Ra itch receptor is exclusively expressed by these cells 17, 18, 29, 48 . The somatostatin primary sensory neurons are molecularly distinct from MrgA3 neurons 17, 18 (Fig. 2) and therefore represent an additional population of pruriceptive afferents.
There has been great interest in determining the mechanisms by which circuits in the spinal cord integrate and modify incoming sensory signals. We studied the effects of activating dynorphin neurons, most of which represent a subset of B5-I cells. Consistent with the suggestion that B5-I cells include neurons responsible for suppressing itch 15 , and that KOR agonists act locally within the spinal cord to reduce itch ( Fig. 6 and ref. 15 ), we found that chemogenetic activation of these neurons suppressed pruritogen-evoked itch behavior (Fig. 4 ). Furthermore, in line with the view that somatostatin-induced itch is mediated through a disinhibitory mechanism, activating the dynorphin neurons also attenuated scratching evoked by intrathecally administered octreotide (Fig. 4f ). This antipruritic role was specific for the dynorphin neurons, since activating the other main class of B5-I cells, those that express nNOS, reduced responses to noxious stimuli but had no effect on itch behavior.
Previously, Duan et al. reported that dynorphin + spinal cord neurons have a role in gating mechanical pain, since mice lacking dynorphin-lineage neurons were hypersensitive to mechanical stimulation but showed normal itch behavior 9 . These studies used the same Pdyn Cre line; however, our experimental approach differed substantially from that of Duan et al. We engineered mice in which mature dynorphin neurons express DREADDq, whereas Duan et al. used an intersectional ablation strategy. This would have captured inhibitory interneurons that transiently express dynorphin 13 , but apparently excluded excitatory dynorphin cells, as well as ~40% of the galanin + inhibitory neurons (see Fig. 5 and Supplementary Fig. 7 of Duan et al.). Because of these differences, the neurons we activated only partially overlap with those that they ablated. This presumably accounts for the difference in our findings with mechanical pain tests and for the discrepancy between the antipruritic effect that we observed and the lack of a significant effect on itch reported in their study.
Our findings reveal that somatostatin is also important in controlling pain (Fig. 8 ). In particular, they suggest that somatostatin released from primary afferents tonically suppressed responses to noxious heat. This resolves previous conflicting reports, which suggested that somatostatin could either promote or attenuate pain [20] [21] [22] [23] [24] . It has long been known that activity in pain pathways can suppress itch 49 . Notably, our findings suggest that somatostatin released by pruriceptive primary afferents suppresses pain, meaning that itch may also inhibit pain.
The activity in pruriceptors in the skin is conveyed via the spinal cord to the brain, where the perceptual quality of itch is produced. By investigating the function of somatostatin in spinal processing, we show that it plays important roles in transmitting and integrating sensory information. In particular, we demonstrate a mechanism whereby two neuropeptides, somatostatin and Nppb, that are released from the same primary afferent, cooperate in a modalityspecific dorsal horn circuit that underpins the evolutionarily important sensation of itch.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-018-0119-z.
Animals. Mice were 20-to 30-g and 2-4 months old, unless otherwise stated. The following lines: Sst tm2.1 (cre) 50 , Ai32 51 , Ai9 52 , Pdyn Cre53 , nNOS CreERT250 , Lbx1 cre54 , Tg(Trpv1 cre ) 55 , Wnt1 cre56 and Sst f/f (Sst tm1 (KOMP) ) were bred and intercrossed to generate experimental animals as described in the text. All experiments using mice followed NIH guidelines and were approved by either the National Institute of Dental and Craniofacial ACUC or the Ethical Review Process Applications Panel of the University of Glasgow and performed in accordance with the UK Animals (Scientific Procedures) Act 1986.
The targeted JM8A3 ES-cell clone F04 with knock-in insertion into the Sst gene was obtained from MBP UC Davis and used to generate chimeric mice. Chimeras were crossed with C57BL6 and then with Gt(ROSA)26Sor tm1(FLP1) mice to produce animals with a Cre-dependent conditional Sst allele consisting of loxP sites surrounding exon 2. These mice were next crossed with Trpv1 cre , Wnt1 cre and Lbx1 cre mice to produce conditional-knockout mice; controls were homozygous Sst f/f littermates without Cre. Age-and sex-matched Sst f/f cKO mice and littermates were used, and there were no substantial phenotypic differences between sexes. Genotyping was performed with TGGTGAGATTATGAAGAGCAAGCG, GGCAGCTGTTCCCAATAGCCATC for wild-type alleles and TGGTGAGATTATGAAGAGCAAGCG, ATCATTAATTGCGTTGCGCCATCTC for mutant alleles.
Animals were maintained in a temperature-controlled environment with a 12-h light/dark cycle and free access to food and water. Mice were group-housed with 4 or 5 animal per cage, except following surgical procedures when they were singly housed. Unless otherwise noted, male C57BL/6 N mice (Charles River) at least 6 weeks old were used for pharmacological and conjugated-peptide ablation studies.
Optogenetic stimulation. For light-mediated activation of trigeminal somatostatin neurons, Sst cre ;Ai32 mice were implanted with a 200-µ m diameter optical fiber (Thorlabs) positioned within 1 mm of the ganglion. Briefly, mice were anesthetized and mounted in a stereotaxic frame (Stoelting, USA). The skull was exposed and a hole drilled and fiber implanted with the following coordinates: Z, 6.1 mm; X, 1.2 mm; Y, 2.0 mm from bregma. The cannula was secured using acrylic dental cement, and after the cement dried, the skin was trimmed and glued. Mice were allowed to recover and experiments were initiated approximately 3 weeks after surgery.
To measure optogenetically elicited behavior, mice were placed in clear plastic enclosures with an optical cannula that could rotate to allow free movement of the mouse. Behavioral responses were recorded during the experiment. Mice were habituated for 30 min with the tethered optical cannula. Light was delivered from a Thorlabs LED driver (1,000 mA, 20 Hz). For all animals, scratching bouts were counted for 30 min without illumination, followed by 30 min with continuous 20-Hz, 590-nm light and finally, bouts were counted over 30 min with continuous 20-Hz, 470-nm illumination. Counts of scratching bouts for individual animals were averaged over two sessions performed on consecutive days. Separate C57BL/6 N mice were assessed for histamine-evoked scratching (10 μ L injected into the cheek).
For in vitro testing of the optogenetic excitation of somatostatin primary afferent neurons, DRGs from Sst Cre ;Ai32 mice were incubated with 5 mg/mL collagenase/dispase for 30 min and were mechanically dissociated. Dissociated primary cultures were seeded onto poly-d-lysine-treated cover slips. DRG neurons were cultured with Dulbecco's Modified Eagle Medium/F-12 supplemented with 10% FBS, 100 U/mL penicillin and 100 µ g/mL streptomycin, nerve growth factor (100 ng/mL) and glial-cell-derived neurotrophic factor (50 ng/mL) for 2-4 d. Whole-cell recordings were performed on DRG neurons expressing ChR2-YFP with an Axon 700B amplifier, 1440 Digitizer and pCLAMP 10 software (Molecular Devices). Bath solution contained 140 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES. Pipette solution contained 140 mM KCl, 10 mM EGTA, 10 mM HEPES, 3 mM Mg-ATP, 0.5 mM Na-GTP. Light pulses were generated by Prizmatix blue LED fiber-coupled LED light source and Prizmatix pulser in the following setting: 1 Hz, 25 ms/975 ms (on/off); 5 Hz, 25 ms/175 ms; 20 Hz, 25 ms/25 ms; 40 Hz, 10 ms/15 ms.
Chemogenetic activation. Intraspinal injections were performed by using a modification of the method described by Foster et al. 31 . Mice were anesthetized with isoflurane and placed in a stereotaxic frame with 2 vertebral clamps attached to the T12 and L1 vertebrae. The spaces between the laminae of T12-T13 and T13-L1 vertebrae were exposed, and a small incision was made in the dura on the right side of the midline in each space. A hole was drilled through the lamina of the T13 vertebra on the right hand side, and an incision was also made through the dura beneath this hole. Drilling a hole through the lamina of T13, rather than removing the lamina, was used to minimize swelling and distortion of the underlying spinal cord. Injections of 300 nL of the virus (AAV2.flex.hM3Dq-mCherry; University of North Carolina Vector Core; 7.7 × 10 8 GC in 300 nL of diluent) were made on the right side through each of these three incisions in the dura at a depth of 300 μ m below the spinal cord surface and 400 μ m lateral to the midline. To minimize leakage, the pipette was removed 5 min after the completion of each injection. Injections were made at a rate of 30 nL per min with a 10-μ L Hamilton syringe attached to a glass micropipette (inner tip diameter, 40 μ m) using a syringe pump (Pump 11 Elite; Harvard Apparatus, Holliston, MA). The locations of the three injection sites described above were chosen to correspond to spinal segments L3, L4 and L5. Baseline behavioral tests (von Frey, Hargreaves and rotarod; see below) were performed 2 d before the operation, and further behavioral tests were carried out on two separate occasions (2 d apart) approximately 2 weeks after surgery. Mice were at least 6 weeks old when the postoperative behavioral tests were carried out. The first of these sessions involved intradermal injection of CQ into the calf and the rotarod test, and the second session consisted of von Frey and Hargreaves tests. For the experiments involving nNOS CreERT2 mice, the animals received two IP injections of tamoxifen (3 mg tamoxifen in 0.15 mL corn oil) on two consecutive days starting on the third or fourth day after surgery. For each of the two postoperative behavioral testing sessions, mice were randomly assigned to CNO (CNO 5 mg/kg) or vehicle IP injection groups (https://www.random. org), and the experimenter was blind to treatment type. The assignment of mice to the treatment groups was independent for each behavioral session, so that an individual animal could receive either the same treatment (CNO or vehicle) or different treatments for the two sessions. Tests were performed between 1 and 5 h after CNO or vehicle injections 31 . Thermal sensitivity was tested with a Hargreaves apparatus (IITC, Woodland Hills, CA, USA). Animals were acclimatized for 1 h in a plastic cage on a glass plate warmed to 25 °C, and then a radiant heat source was targeted to the ipsilateral (right) hindpaw 5 times with a 10-min interval between tests. The time taken to lift the stimulated paw was measured. A cutoff time of 25 s was used to prevent tissue damage. Mechanical sensitivity was tested with von Frey hairs. Animals were acclimatized in a plastic cage with a wire mesh floor for 1 h and then tested with von Frey filaments with logarithmically incremental stiffness (starting at 0.4 g). Each filament was applied for 5 s, and the presence or absence of a withdrawal response was noted. The filament with the next incremental stiffness was then applied, depending on the response to the previous filament, and this was continued until there had been six positive responses. The filaments were applied to the glabrous skin on the right hindpaw, and a positive response was recorded when there was lifting or flinching of the paw. The 50% withdrawal was determined by the up-down method 57 . To test for itch, mice were acclimatized for 2 h in plastic observation chambers that were surrounded by mirrors such that the experimenter had an unobstructed view of the hindlimb 15 . We injected 100 μ g chloroquine dissolved in 10 μ l PBS intradermally into the front of the right calf, which had been shaved at least 48 h previously. In each case, the success of the intradermal injection was confirmed by the presence of a bleb 58 . Mice were video-recorded for 30 min after the CQ injection, and the amount of time spent biting and licking the injection site was scored later offline. Motor coordination was tested using a rotarod (IITC) with the rod programmed to accelerate from 4 to 40 rpm over 5 min. During the experimental testing session, the mice were allowed two trial runs followed by four test runs, and the average of the maximum rpm tolerated was recorded. For each mouse, the ratio of maximum rpm during CNO/vehicle treatment to the preoperative maximum rpm was determined. There was no significant difference in these ratios between CNO-treated and vehicletreated mice in either the Pdyn Cre or nNOS CreERT2 experiments (P = 0.1 and P = 0.29, respectively; two-sided t test). Mice of both sexes were used in this part of the study, and no significant behavioral differences were observed between sexes.
For intrathecal injections, we used the method described previously 59 to administer AAV2.flex.hM3Dq-mCherry; 5.1 × 10 9 GC in 10 µ L of saline. Mice were anesthetized with isoflurane. The caudal paralumbar region, just cranial to the iliac crests, was securely held by the thumb and middle fingers of the left hand, and the index finger was placed on the tip of sixth lumbar (L6) spinous process, the highest point of the vertebral column. All intrathecal injections were delivered in a total volume of 10 μ L. The needle was inserted into the fifth intervertebral space (L5-L6), causing a sudden lateral movement of the tail. The needle was held in position for 10 s and removed slowly to avoid outflow. Behavioral assays began 14 d after virus injection, and animals were treated with 1 mg/kg CNO 60 . One hour after CNO or vehicle injection, pruritogens were injected intradermally into the nape of the neck (histamine or chloroquine), or delivered intrathecally (octreotide), and scratching bouts counted over 30 min.
Conjugated peptide-mediated cell ablation. Ablation of Npr1-and GRPRexpressing spinal cord interneurons was accomplished by intrathecal (segment L3/4) injection of Nppb-saporin (4 µ g in 10 µ L; Advanced Targeting Systems) and GRP-saporin (2.5 µ g) respectively. We have previously shown that these treatments are highly selective for the corresponding neuronal populations 3 . Behavioral assays were initiated 2 weeks after toxin injection.
Itch behavioral test. All other itch tests were performed as previously described 3 . Briefly, mice were habituated for 1 h at room temperature (18-22 °C) in separate, clear, plastic containers (10 × 10 × 12 cm). The experimenter was blinded to genotype. Itch-inducing substances histamine (100 μ g), chloroquine (100 μ g), SLIGRL-NH 2 (100 μ g), 2-methyl serotonin (30 μ g), endothelin (25 ng) and compound 48/80 (100 μ g) were injected intradermally into the nape of the neck (10 µ L), and numbers of scratching bouts directed to the nape of the neck assessed over 30 min. We cannot completely eliminate the possibility that we were observing nociceptive rather than pruritic behaviors, but since we used established pruritogens in these assays we interpret the scratching responses we measured as itch behaviors. Itch behavior was also elicited by lumbar 4-5 vertebrae intrathecal injection of Nppb (5 µ g in 10 µ L), GRP (1 nmol in 10 µ L), and octreotide (10 ng or 100 ng in 10 µ L, as indicated in the text), all prepared in saline. Intrathecal pretreatment with GRP antagonist deamino-Phe19,D-Ala24,D-Pro26-D-Phe27-GRP (1 nM in 10 µ L) was used to block GRPR; Sst2-selective antagonist CYN 154806 (1 µ g in 10 µ L) was used to block Sst 2a receptors; the kappa-opioid receptor antagonist norbinaltorphimine (nor-BNI, 100 µ g in 10 µ L) was used to block kappa-opioid receptors; and the kappa-opioid receptor agonist ICI199441 (0.1 µ g in 10 µ L) was used to activate kappa-opioid receptors. All were prepared in saline. We performed intrathecal injections with the same volume of dye solutions as we used in our assays and observed staining of lumbar, thoracic and cervical regions of the spinal cord, showing that this route of administration causes injected agents to spread along the entire spinal cord. The intrathecal administration of known pruritic agents, for example, GRP and octreotide, predominantly resulted in scratching directed toward the nape of the neck, and we observed only minor lower body evoked responses. Since the nape of the neck appears to be particularly sensitive to intrathecal administration, we recorded this behavior.
In situ hybridization. Single-and double-label ISH was performed at high stringency as described previously 3 . The probe used to test Sst f/f mice corresponded to the entire exon 2 of Sst. ISH experiments quantifying overlap of somatostatin with Nppb and of somatostatin with tdTomato were performed on 2-3 sections prepared from 3 wild-type and 3 Sst Cre ;Ai9 mice, and representative images are displayed. RNAscope, a multiplexed fluorescent in situ hybridization technique (Advanced Cell Diagnostics), was performed according to the manufacturer's instructions on fresh frozen tissue sections.
Behavioral testing of Sst f/f mice. Thermal sensitivity was tested with a Hargreaves apparatus (Ugo-Basile). Animals were acclimatized for 1 h in a plastic cage on a glass plate. A radiant heat source was targeted to the plantar surface of the hindpaw and withdrawal latency measured. A cutoff time of 20 s was used to prevent tissue damage. For von Frey measurements, mice were acclimatized in a plastic cage with a wire mesh floor for 1 h and then tested with von Frey filaments with logarithmically incremental stiffness (starting at 0.4 g). Each filament was applied for 5 s to the hindpaw, and the presence or absence of a withdrawal response was noted. The filament with the next stiffness was then applied, depending on the response to the previous filament, and this was continued until six positive responses were recorded. The 50% withdrawal was determined by the up-down method 57 .
Immunocytochemistry for chemogenetic experiments. All of the mice that had received intraspinal injections of AAV2.flex.hM3Dq-mCherry were deeply anaesthetized with pentobarbital (30 mg i.p.) and perfused with 4% freshly depolymerized formaldehyde, after completion of the behavioral experiments. The lumbar enlargement (L3-5 segments) was postfixed for 2 h and cut into parasagittal sections with a vibrating blade microtome. These were processed for immunocytochemical staining as described previously 61 . The sections were incubated in anti-mCherry (rabbit antibody, Abcam, ab167453, 1:2,000) for 3 d at 4 °C, and this was revealed with fluorescence-labeled species-specific secondary antibodies (Jackson ImmunoResearch, West Grove, PA, USA). All antibodies were diluted in phosphate-buffered saline containing 0.3% Triton X-100 and 5% normal donkey serum. Sections were scanned with a Zeiss LSM 710 confocal microscope to confirm adequate expression of the hM3Dq-mCherry fusion protein in the appropriate spinal segments. In two cases, intraspinal injections were not successful, as judged by lack of mCherry staining in the appropriate spinal segments, and for these mice the corresponding behavioral data were excluded from the study.
To determine the neurochemical phenotype of neurons that expressed the mCherry fusion protein and to examine c-Fos staining following chemogenetic activation, an additional 5 mice of each genotype received intraspinal injections of AAV2.flex.hM3Dq-mCherry into the L3 and L5 segments. These mice were injected with either CNO (n = 3 mice per genotype) or vehicle (n = 2 mice per genotype), and 2 h later they were perfused with fixative, as described above. Transverse spinal cord sections were cut from the L3 and L5 spinal segments. Sections from nNOS CreERT2 mice were immunostained for mCherry (chicken antibody Abcam, ab205402, 1:10,000), nNOS (rabbit antibody, Millipore, 07-571, 1:2,000), Sst 2a (guinea pig, Gramsch Laboratories, SS-870, 1:2,000) and c-Fos (goat antibody, Santa Cruz biotech, sc52-G, 1:2,000). Sections from Pdyn Cre mice were reacted for mCherry (chicken antibody), Sst 2a , Pax2 (rabbit antibody, Life Technologies, 716000, 1:1,000) and c-Fos. Two sections from each mouse were analyzed with Neurolucida software (MBF, Bioscience, Williston, VT, USA). All cells in the superficial dorsal horn (laminae I-II) that were mCherryimmunoreactive were identified. The stained neurons were then examined for the presence of the other markers. In addition, to determine the proportion of c-Fos + cells that were mCherry-immunoreactive, we counted neurons that were c-Fos + but lacked mCherry. Note that for technical reasons we did not use antibodies against preprodynorphin (PPD), as our PPD antibody is raised in guinea pig, the same species as the Sst 2a antibody; and in addition, PPD may be below the detection threshold to allow unambiguous identification of all dynorphinexpressing neurons.
Both mCherry antibodies were raised against recombinant full-length protein corresponding to mCherry. Specificity was demonstrated by finding an identical distribution of staining to that seen with native fluorescence of mCherry protein and by the lack of staining in regions of tissue that do not contain mCherry. The c-Fos antibody was raised against a peptide corresponding to the N-terminus of human Fos, and its specificity has been shown in previous studies by the restriction of staining to neurons in somatotopically appropriate areas after noxious or pruritic stimulation 61 . The nNOS antibody was directed against a synthetic peptide corresponding to the N-terminus of rat nNOS and labels a single band of 155 kDa in rat brain extracts. The antibody against Pax2 was raised against amino acids 188 to 385 of the mouse protein and recognizes bands of the appropriate size on western blots of mouse embryonic kidney 62 . The Sst 2a antibody was generated against the C-terminal 15 amino acids of the mouse receptor, and staining is abolished by incubation with the immunizing peptide (manufacturer's specification).
Distribution of excitatory and inhibitory dynorphin cells. Three wild-type C57BL/6 mice (either sex, 19-20 g) were perfused with fixative as described above. Spinal cord segments L3, L4 and L5 were removed from all three mice and C6, C7 and C8 from two mice. In each case, the segments were cut into four sets of transverse sections, one of which was immunoreacted to reveal Pax2, PPD and NeuN and one that was treated to reveal VGLUT3. The tyramide signal amplification method (TSA kit tetramethylrhodamine NEL702001, PerkinElmer Life Sciences, Boston, MA, USA) was used to reveal PPD and VGLUT3. Two or three sections that had been reacted with the first antibody combination were analyzed using a modification of the dissector method 13 . All PPD-immunoreactive neurons with the bottom surface between reference and look-up sections were initially plotted onto an outline of the dorsal horn, and then the presence or absence of Pax2 staining was recorded for each selected cell. The sections that had been reacted with VGLUT3 antibody were then examined, and those that were closest in appearance to the sections analyzed for PPD were scanned. The medial edge of the band of VGLUT3 staining, which represents hairy skin territory, was located and added to the outline drawing. The PPD antibody 63 was raised against a peptide corresponding to amino acids 229-248 at the C-terminus of rat PPD, and has been shown to label PPD but not dynorphin or enkephalin. The NeuN antibody was raised against cell nuclei extracted from mouse brain and found to react with a protein specific for neurons 64 , which has subsequently been identified as the splicing factor Fox-3. The antibody against VGLUT3 was raised against amino acids 522-588 of the mouse protein and detects a single protein band at 60-62 kDa.
Somatostatin action on dynorphin cells. Eight
Pdyn Cre mice of either sex (18-23 g, aged 5-9 weeks) received intraspinal injections of AAV.flex.eGFP (4.3 × 10 8 to 1.7 × 10 9 GC in 300 nL diluent). These were performed as described above, except that injections were made through incisions on either side of the T13 vertebra into the L3 or L5 segments, and the mice survived between 7 and 11 d after surgery.
Five of these animals were used for electrophysiological experiments. The animals were decapitated under general anesthesia with isoflurane (1-3%). Spinal cords were isolated in ice-cold dissecting solution that contained the following (in mM): 3.0 KCl, 1.2 NaH 2 PO 4 , 0.5 CaCl 2 , 1.3 MgCl 2 , 8.7 MgSO 4 , 26 NaHCO 3 , 20 HEPES, 25 glucose, 215 sucrose, oxygenated with 95% O 2 and 5% CO 2 . The dura mater was removed, and ventral and dorsal roots were trimmed close to the cord. The lumbar segments containing the injection site were cut into parasagittal slices (300 μ m) with a vibrating blade microtome (MicromHM 650 V, Fisher Scientific). Slices were held in the dissecting solution at room temperature (18-22 °C) for at least 30 min, and then transferred into recording solution that contained the following (in mM): 126 NaCl, 3.0 KCl, 1.2 NaH 2 PO 4 , 2.4 CaCl 2 , 1.3 MgCl 2 , 26.0 NaHCO 3 , 15 glucose, oxygenated with 95% O 2 , 5% CO 2 . GFP + cells found within the superficial dorsal horn (mostly lamina II) were targeted for whole-cell patch-clamp recording, under fluorescent and infrared differential interference contrast microscopy on an Olympus BX51WI microscope. Patch pipettes were pulled with a horizontal puller (P-97, Sutter Instruments) from glass capillaries (Harvard Apparatus). The pipettes typically had an electrical resistance of 4-6 MΩ when filled with internal solution, which contained the following (in mM): 130 potassium-gluconate, 10 KCl, 2 MgCl 2 , 10 HEPES, 0.5 EGTA, 2 ATP-Na 2 , 0.5 GTP-Na, pH adjusted to 7.3 with 1 M KOH. Neurobiotin (0.2%, Vector Laboratories) was also included in the internal solution for subsequent identification of recorded cells. Patch-clamp signals were amplified and filtered (4-kHz lowpass Bessel filter) with a MultiClamp 700B amplifier (Molecular Devices) and acquired at 10 kHz using a Digidata 1440 A A/D board and pClamp 10 software (Molecular Devices). When whole-cell mode was established, the cell was presented with voltage and current step protocols for assessment of its intrinsic membrane properties. While holding the cell at -60 mV, voltage steps from -90 to -50 mV (500 ms, 5-mV increments) were applied in order to allow the currentvoltage (I-V) relationship to be obtained. In current-clamp mode, steps of square current pulse (1 s) were injected to evoke action potentials. Patterns of action potential firing were classified as described previously 38 . To minimize the chance of sampling excitatory interneurons, we excluded cells that showed delayed or gap firing patterns, which are associated with an excitatory phenotype 38 . Somatostatin (2 μ M, Tocris Bioscience) was administered via the recording solution, and any change in membrane potential was recorded in current-clamp mode. Around 5 min after the start of somatostatin application, the same voltage and current step protocols were repeated to assess somatostatin-mediated modulatory effects in the recorded cell (n = 8).
Three of the Pdyn Cre mice that had received intraspinal injection of AAV. flex.eGFP were deeply anaesthetized and perfused with fixative. Injected spinal cord segments were removed and processed for immunocytochemistry as described above. Parasagittal sections were immunoreacted to reveal Sst 2a , somatostatin (rabbit antibody, Peninsula labs, T-4103, 1:500) and VGLUT2 (chicken antibody, Synaptic Systems, 135416, 1:500). Five eGFP + cells that were Sst 2a -immunoreactive were selected from each mouse before immunostaining for somatostatin was observed, and these were scanned with a confocal microscope to include as much of the dendritic tree as was visible in the section. The cell bodies and dendritic trees were reconstructed with Neurolucida software based on eGFP fluorescence. The other channels were then viewed, and contacts from somatostatin + VGLUT2 + boutons were marked. The VGLUT2 antibody was raised against a synthetic peptide corresponding to amino acids 566-582 of rat VGLUT2 and detects a single band of appropriate molecular weight on western blots (manufacturer's specification). The somatostatin antibody is reported to show 100% cross-reactivity with somatostatin-28 and somatostatin-25, but none with substance P or neuropeptide Y, and staining is blocked by preincubation with somatostatin 65 .
Statistical analysis. Data are expressed as mean ± s.e.m. Statistical analysis was performed in Prism (GraphPad). Differences between two groups were examined using a two-sided Student's t test, with P < 0.05 considered significant and P > 0.05 considered nonsignificant. When comparisons were made between different groups of mice, ANOVA was used and when repeated effects were assessed in a single group of mice ( Fig. 2 only) repeated-measures ANOVA was used. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications 4, 19, 46 . Data distribution was assumed to be normal, but was not formally tested. Data collection was not randomized, and data analysis and collection were not performed blind to the conditions of the experiment except where noted (chemogenetic experiments). Animals and data points, except where noted, were not excluded from analysis. All relevant data are available from authors. 
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